Printer Friendly

The Effect of Chunghyul-Dan on Hyperventilation-Induced Carbon Dioxide Reactivity of the Middle Cerebral Artery in Normal Subjects: A Dose-Dependent Study.

1. Introduction

Chunghyul-dan (CHD) is an herbal complex containing 80% ethanol extract and is composed of Scutellariae Radix, Coptidis Rhizoma, Phellodendri Cortex, Gardeniae Fructus, and Rhei Rhizoma. Previous studies have reported that CHD has antihyperlipidemic effects [1, 2]; improves arterial stiffness [3]; and has anti-inflammatory [4, 5], antioxidant [6], antihypertensive [7], and neuronal protective [8-10] effects. Furthermore, CHD reportedly results in nitric oxide synthase (NOS) mRNA expression in endothelial cells [11], which may affect NO endothelial function. In addition, owing to its inhibitory effects on the recurrence of small vessel occlusion-type cerebral infarction [12], CHD has been used as an ischemic stroke preventive agent.

Small vessel occlusion-type cerebral infarction is caused by blood-brain barrier damage induced by cerebral endothelial dysfunction [13], impaired cerebral autoregulation (CA) [14], and prothrombotic changes [15]. Among them, CA is largely attributed to two factors: blood pressure variability [16] and carbon dioxide (C[O.sub.2]) cerebrovascular reactivity (CVR) [17]. However, cerebral blood flow remains constant at a mean blood pressure of 60-150 mmHg, while it is immediately sensitive to the concentration of C[O.sub.2]. Therefore, CVR is an important factor in the control of CA. CVR might be reduced in various pathological conditions such as hypertension [18], diabetes mellitus [19, 20], heart failure [21], arterial stenosis or occlusion [22], aging [23], cognitive impairment [24], depression [25], Alzheimer's disease [26], and white matter degeneration of the brain [27]. Furthermore, decreased CVR is known to increase the risk of ischemic stroke [28, 29]. In a previous meta-analysis, the usefulness of CVR for prediction of ischemic stroke in carotid artery stenosis and occlusion was evaluated. Seven hundred fifty-four patients (9 prospective studies) were included and impaired CVR was independently associated with an increased risk of ischemic stroke (p < 0.0001) [28].

The inhibitory effect of CHD on the recurrence of small vessel occlusion-type cerebral infarction is believed to be due to the control of stroke risk factors and improved endothelial function. However, previous studies suggested that systemic and cerebral endothelial functions are independent of each other [30, 31]. Thus, it is unclear whether CHD could also affect cerebral endothelial function. In addition, it remains undetermined whether CHD directly affects cerebral blood flow. Therefore, it is difficult to explain the inhibitory effect of CHD on the recurrence of ischemic stroke. Thus, it is necessary to measure the CVR, which is a predictor of the risk of ischemic stroke and an important factor in the control of cerebral blood flow, in order to explain the inhibitory effect of CHD on the recurrence of small vessel occlusion-type cerebral infarction. CVR was assessed as the degree of cerebral blood flow change with C[O.sub.2] or acetazolamide injection, which is a vasoactive factor. CVR is directly and indirectly measured using transcranial Doppler sonography (TCD), blood oxygen level-dependent functional magnetic resonance imaging (BOLD fMRI), single photon emission computed tomography (SPECT), and positron emission tomography (PET). Among them, TCD is widely used because it is relatively easy and economical to measure CVR using this noninvasive method.

Thus, we assumed that administration of CHD would directly increase the CVR and prevent small vessel occlusion-type cerebral infarction. To confirm this hypothesis, we observed cerebral hemodynamics before and after the administration of CHD via hyperventilation-induced C[O.sub.2] reactivity and corrected cerebrovascular velocity (correction of end-tidal C[O.sub.2] partial pressure to 40 mmHg) measured using TCD. Although hypercapnia CVR has larger evidences on stroke risk, we used hyperventilation-induced C[O.sub.2] reactivity to minimize the influence of concentration of C[O.sub.2] on cerebral blood flow during study protocol. In addition, we measured CVR for 300 mg, 600 mg, and 1200 mg doses of CHD and no-use in order to determine the optimal dose of CHD.

2. Materials and Methods

2.1. Subjects. Twelve healthy male volunteers (mean age: 26.3 [+ or -] 1.1 (SD; standard deviation) years) were recruited. The subjects had no history of cerebrovascular disease, heart diseases, hypertension, diabetes mellitus, thyroid disease, or psychiatric problems. All subjects were prohibited from consuming alcohol, coffee, smoking, and any medications for 12 hours before the trial.

2.2. CHD Preparation. The CHD was manufactured by the Pharmaceutical Department of Kyung Hee University Korean Medicine Hospital. Total of 1.2 g of Scutellariae Radix, Coptidis Rhizoma, Phellodendri Cortex, Gardeniae Fructus, and Rhei Rhizoma was extracted by refluxing with 15-fold volume of 80% ethanol for 2 hours, filtered, and concentrated under reduced pressure to reduce the water content to 50%. The detailed component of CHD is shown in Table 1.

2.3. Study Design. This study employed an open-label, randomized, and multiple-crossover trial design. The subjects visited four times at 8 AM after fasting. At the first visit (visit 1), only water was administered to the subjects. In subsequent visits (visits 2-4), three doses of CHD (300, 600, or 1200 mg) were randomly administered to the subjects. In addition, the intervals between each visit were least 1 week in order to minimize the residual effects of the CHD.

2.4. Assessment Methods. The cerebral blood flow velocity and CVR of the middle cerebral artery were measured using a Multi-Dop X4 cerebral blood flow ultrasound (transcranial Doppler) system (Compumedics DWL, Singen, Germany) as described previously [32-34]. At each visit, the cerebral blood flow velocity of the middle cerebral artery was measured in the unilateral temporal window using a 2 MHz ultrasonic probe with the participant in a supine position. The probe was fixed to the temporal window using a detachable bilateral probe holder (LAM-Rack; Compumedics DWL). The depth for detecting the middle cerebral artery was 45 to 60 mm and the best waveforms were recorded. After stabilization for five minutes before measurement, the mean cerebral blood flow velocity was recorded, followed by a four-minute rest and one-minute hyperventilation. The mean cerebral blood flow velocities in the middle cerebral artery were measured at rest in the normocapnic state and in the hypocapnic state during hyperventilation. All TCD waveforms were stored in the computer for analysis.

CVR is the percentage difference in mean cerebral blood flow velocity according to the change of [mathematical expression not reproducible] and is expressed as %/min according to the following formula:

[mathematical expression not reproducible], (1)

where [V.sub.rest] is blood flow velocity at rest (the most stable 10 seconds measured), [V.sub.hypocapnia] is blood flow velocity during hyperventilation (the most stable 10 seconds measured in the second half of 30 seconds), and [mathematical expression not reproducible] is difference in [mathematical expression not reproducible] between the two periods.

A corrected cerebral blood flow velocity (CV40, cm/s) was used, which was converted into a 40 mmHg C[O.sub.2] concentration according to a previously suggested formula [35] because cerebral blood flow velocity is affected by the blood concentration of C[O.sub.2].

CV40 (Corrected Velocity at [P.sub.ETCO2] 40 mmHg) = [V.sub.1] x [e.sup.b(PCO2 40 mmHg-P1CO2)] (2)

b is C[O.sub.2] reactivity, V1 is blood flow velocity of P1CO2, and [P.sub.ETCO2] is end-tidal C[O.sub.2] partial pressure.

To measure and control for variables such as blood pressure, pulse rate, and expiratory C[O.sub.2] concentration, various modules of the Cardiocap S/5 collector (Datex-Ohmeda, Helsinki, Finland) were used in a quiet room maintained at a constant temperature. Blood pressure and pulse rate were measured before hyperventilation. Blood pressure was recorded as mean blood pressure measured 3 times at 2-minute intervals with a cuff wrapped around the left upper arm; pulse rate was measured continuously using an oximeter placed on the right finger of the subject. Nasal prongs connected to the Cardiocap S/5 collector were placed in the nose of the subject. During the trial, the subjects were instructed to breathe only with nasal breathing and C[O.sub.2] concentration was monitored during expiration. The pulse rate and C[O.sub.2] concentration values stored in the Cardiocap S/5 collector program were averaged over a specific time using the snapshot function. The above three parameters were continuously monitored during the trial and stored on a computer connected to the Cardiocap S/5 collector.

We used these measuring devices to repeatedly measure C[O.sub.2] reactivity, CV40, and blood pressure at 1, 2, and 3 hours after the oral administration. Each measurement point required approximately 15 minutes to complete; during this time, the above devices were attached in order to record and store the measured parameters (Figure 1).

2.5. Statistical Analysis. The statistical analyses in this study were performed using Statistical Package for the Social Sciences version 12.0 for Windows (SPSS, Inc., Chicago, IL). All data were expressed as mean [+ or -] standard deviation (SD). The changes according to the time and dose after the administration of CHD or water were analyzed by two-way repeated measures analysis of variance (ANOVA). In addition, one-way repeated measures ANOVA with Bonferroni correction was used for comparison (at the same time or the same dose).

Finally, correlations between CVR and CV40 were assessed by Pearson's correlation analysis. p values less than 0.05 were considered statistically significant.

3. Results

3.1. CVR (%/min). Two-way ANOVA with repeated measures showed a significant interaction with time x treatment (F = 10.720, p < 0.001). In Bonferroni post hoc analysis, the 600 mg group showed significant differences compared with the control and 300 mg groups (p = 0.024 and 0.023, resp.). Furthermore, the 1200 mg group also showed significant differences compared with the control and 300 mg groups (p = 0.034 and 0.044, resp.).

There was no significant difference in the one-way repeated measures ANOVA in the control and 300 mg CHD groups. However, there were significant interactions with time (p < 0.001) in the groups given 600 and 1200 mg of CHD. Pos thoc analysis revealed statistically significant differences at 1 (T1, p = 0.001), 2 (T2, p < 0.001), and 3 (T3, p < 0.001) hours after administration of 600 mg CHD compared to the before CHD administration (T0). There were also statistically significant differences at 2 (p = 0.002) and 3 (p < 0.001) hours after administration of 1200 mg CHD compared to the before CHD administration (T0) (Table 2).

The changes in CVR expressed as percent (%) of baseline value were analyzed using one-way repeated measures ANOVA with Bonferroni correction for each dose group at the same time point. In the group given 600 mg CHD, there were statistically significant differences compared with the control group at 1, 2, and 3 hours after administration (p = 0.006, p < 0.001, and p = 0.001, resp.) and there were also statistically significant differences compared with the 300 mg group at 2 and 3 hours (p < 0.001, and p < 0.001, resp.). Furthermore, there were statistically significant differences compared with the control group at 2 and 3 hours after administration in the group given 1200 mg CHD (p = 0.005 and p < 0.001). There were also statistically significant differences at 2 and 3 hours after administration compared with the group given 300 mg (p = 0.005, p < 0.001) (Figure 2).

3.2. Results of Corrected Cerebral Blood Flow Velocity (CV40, cm/s). The corrected cerebral blood flow velocity showed a significant interaction (F = 3.227, p = 0.002) for time x treatment, but the difference between the treatment groups was not significant (Bonferroni post hoc test). When analyzed by treatment group, there was a significant interaction with time in the 600 mg CHD group (p = 0.024). However, there was no significant difference between before CHD administration (T0) and 3 hours after administration (p = 0.075) (Table 3).

The changes in CV40 expressed as percent (%) of baseline value were analyzed by one-way repeated measures ANOVA with Bonferroni correction for each dose group at the same time point. The CV40 value at 3 hours after the administration (T3) of 600 mg CHD was significantly different from that of the control group (p = 0.030). The CV40 values of the 600 mg CHD group were significantly different from those of the 300 mg group at 1, 2, and 3 hours (p = 0.023, 0.034, and 0.001, resp.) (Figure 3).

3.3. Results of Mean Blood Pressure and Mean Heart Rate. There was no significant difference in mean blood pressure and mean heart rate before and after the administration of CHD (all doses) (Table 4).

3.4. Correlation between Changes in CVR and Corrected Cerebral Blood Flow Velocity with Administration of CHD. A significant correlation was observed between the changes of CVR and corrected cerebral blood flow velocities in subjects who were given CHD (Figure 4).

4. Discussion

The CVR and corrected cerebral blood flow velocity (CV40) of the middle cerebral artery measured before and after the administration of CHD (600 and 1200 mg) showed a continuous increase over time. Mean blood pressure and heart rate did not significantly differ before and after the administration of CHD. In addition, no participant complained of adverse effects after taking CHD.

Hyperventilation-induced C[O.sub.2] CVR significantly increased after administration of 600 and 1200 mg CHD. CHD inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase [1]; thus, it may decrease the total cholesterol and low-density lipoprotein- (LDL) cholesterol levels [2]. Furthermore, CHD upregulates mRNA expression of endothelial NOS (eNOS) and leads to the production of NO in vascular endothelial cells [11]. In previous studies, CHD showed anti-inflammatory effects by reducing NO induced by cyclooxygenase-2 (COX-2), interferon gamma (IFN-r), interleukin 4 (IL-4), tumor necrosis factor alpha (TNF-a), prostaglandin E2 (PGE-2), vascular cell adhesion molecule 1 (VCAM-1), monocyte chemoattractant protein-1 (MCP-1), and inducible NOS (iNOS) [4-6]. CHD also showed vascular endothelial protective effects such as antiapoptosis, cell cycle progression, induced cell migration, and proliferation in vascular endothelial cells [36]. Among these various effects of CHD, the action of producing NO in eNOS could improve cerebrovascular endothelial function and increase CVR. Similar studies reported the effects of statin on endothelial NO synthesis and enhancement of CVR. Kaesemeyer et al. [37] reported that statins rapidly activate eNOS in bovine aortic endothelial cells and lead to the production of NO. Sterzer et al. [38] suggested that improvement of CVR after statin administration in small vessel occlusion-type ischemic stroke patients appears with the upregulation of eNOS and blood flow control, which is more reactive to NO. Furthermore, Sander et al. reported that CVR could be also increased by short-term statin administration in healthy subjects [39]. Based on these results, we assumed that the mechanism of CHD on CVR in healthy subjects is similar to the effects of statins. Since CVR decreases after acute stroke and decreased CVR increases the risk of stroke and TIA, the use of CHD could increase CVR and prevent stroke.

Corrected cerebral blood flow velocity (CV40) increased significantly after the administration of 600 mg CHD compared to no treatment. This study measured mean blood pressure, heart rate, and [P.sub.ETCO2], which could affect the cerebral blood flow, but no statistically significant differences were found compared with the resting (normocapnic) condition.

We measured CVR and cerebral blood flow velocity with transcranial Doppler to indirectly estimate the changes in cerebral blood flow. The following research results provide theoretical background to these measurement methods.

Markwalder et al. [35] reported that the change in cerebral blood flow velocity could be a change in cerebral blood flow, since the cerebral blood flow-PC[O.sub.2] response curve was similar to that of the cerebral blood flow velocity-[P.sub.ETCO2], assuming no change in vessel diameter. Sorteberg et al. [40] suggested that cerebral blood flow velocity and local cerebral blood flow were statistically correlated. Lindegaard et al. [41] reported a significant correlation between the cerebral artery flow velocity and internal carotid artery blood flow. Therefore, we suggest that the administration of 600 mg CHD may increase cerebral blood flow. Based on these results, CHD may improve lowered cerebral blood flow states such as hypertension, ischemic stroke, Alzheimer's disease [42, 43], cerebral atrophy, and aging [44, 45].

The present study protocol was not designed to reveal the mechanism. Therefore, the mechanism of the immediate effect of CHD on cerebrovascular reactivity and cerebral blood flow velocity could not be clearly proven. However, the presumed mechanism is as follows. Control of cerebral blood flow through changes in vessel diameter can be divided into endothelium-dependent and endothelium-independent mechanisms. Endothelium-independent vasodilation occurs when NO produced by nonendothelial cells acts directly on vascular smooth muscle or when vascular smooth muscle relaxation occurs because of [Ca.sup.2+] channel inhibition. In normal subjects, changes in cerebral blood flow were not observed after the administration of sodium nitroprusside (SNP) [46, 47] or nitroglycerin [48], which produces NO. In addition, cerebral blood flow velocity was increased when nimodipine, a calcium channel blocker, was administered to patients with subarachnoid hemorrhage [49]. However, there was no significant change in cerebral blood flow velocity and CVR was decreased when nimodipine was administered to healthy subjects [50]. These results suggest that endothelium-independent blood flow regulation has little effect on cerebral blood flow velocity and CVR. Therefore, it is unlikely that the effect of CHD on cerebral blood flow is mediated by an endothelium-independent regulation mechanism, and further studies are needed.

Endothelium-dependent cerebral blood flow regulation is the result of variation of the diameter of vessels due to NO, a vasodilator secreted by vascular endothelial cells, or Endothelin-1, a vasoconstrictor. NO has several effects, including vasodilation, increased blood flow, decreased vessel resistance, decreased blood pressure, inhibition of platelet aggregation and adhesion, antioxidant, and vascular endothelial cell protection [51-53]. Basal NO, which is continuously secreted by the endothelial cells of the cerebral vessels, plays an important role in regulating cerebral blood flow and vascular tone [54]. Cerebral blood flow velocity reportedly increases when L-arginine, which increases NO production in endothelial cells, is administered to normal subjects [55]. In another study, cerebral blood flow velocity did not change after administration of L-arginine, and CVR increased only in subjects with originally decreased CVR [56]. However, administration of NG-Methyl-L-arginine acetate (L-NMMA) inhibited NO synthesis in the elderly, resulting in decreased cerebral blood flow velocity; there was no change in cerebral blood flow velocity and CVR after administration to young healthy persons [57, 58]. These results suggest that the NO increase in endothelial cells observed after the administration of CHD might affect cerebral blood flow. However, increased NO in the endothelial cells increased CVR and cerebral blood flow velocity after the administration of CHD to young healthy subjects. Furthermore, CV40 in 600 mg and 1200 mg CHD group increased over different sessions (T0 to T3) and a significant correlation was observed between the changes of CVR and CV40 in subjects who were given CHD (Figure 4). Therefore, the increased cerebral blood flow velocity could be also one of the main mechanisms of the CVR increase after CHD administration. Therefore, further studies concerned with indicators such as blood viscosity or erythrocyte deformability, which may affect cerebral microcirculation, are needed to determine the concrete mechanism of CHD on CVR.

There was no significant change in CVR and corrected cerebral blood flow velocity (CV40) after the administration of 300 mg or no CHD. However, CVR and CV40 tended to decrease with time. These results are consistent with those of Strohm et al. [59] and Conroy et al. [60], who reported that CVR in normal subjects declined from morning to evening and cerebral blood flow velocity declined from midnight to noon. In this study, CVR and cerebral blood flow velocity decreased with daily fluctuation because the study was conducted from 8:00 to 11:00 AM. This finding suggests that increased CVR and cerebral blood flow velocity after administration of 600 or 1200 mg CHD might be a more significant outcome.

The mean blood pressure and heart rate did not differ significantly following the administration of CHD (or not). Furthermore, the dose of CHD also did not affect the mean blood pressure and heart rate. A previous study showed a significant decrease in systolic blood pressure and no change in pulse rate in patients with acute stroke with hypertension after administering 1200 mg CHD daily for 2 weeks [7]. This difference in blood pressure lowering effect may be due to the single administration of CHD to normal subjects in this study; however, it also did not affect the heart rate.

The limitations of the present study are as follows: the study group contained a small number of subjects, the subjects and researchers were not blinded, and a nonplacebo group was used as a control group. However, in the control group of a previous study [33] that used the same protocol, CVR, CV40, mean blood pressure, and pulse rate of the middle cerebral artery measured after taking the placebo drug were similar to those of the untreated group in this study. Therefore, the nocebo effect may be excluded. Although it was assumed that immediate cerebral blood flow improvement after CHD administration would be an effect of NO production through the activation of eNOS in the vascular endothelial cells, there are some limitations in explaining the concrete relationship, as this study did not measure plasma NO levels. Therefore, future studies with better design are necessary to assess these issues.

https://doi.org/10.1155/2017/4567217

Conflicts of Interest

All authors declare that there are no conflicts of interest.

Authors' Contributions

Chul Jin and Sang-Kwan Moon contributed equally to this work as first authors.

References

[1] Y.-S. Kim, E.-A. Jung, J.-E. Shin et al., "Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase," Biological and Pharmaceutical Bulletin, vol. 25, no. 11, pp. 1442-1445, 2002.

[2] K. H. Cho, H. S. Kang, W. S. Jung, S. U. Park, and S. K. Moon, "Efficacy and safety of Chunghyul-dan (Qingwie-dan) in patients with hypercholesterolemia," The American Journal of Chinese Medicine, vol. 33, no. 2, pp. 241-248, 2005.

[3] S. U. Park, W. S. Jung, S. K. Moon et al., "Chunghyul-Dan (Qingxie-Dan) improves arterial stiffness in patients with increased baPWV," American Journal of Chinese Medicine, vol. 34, no. 4, pp. 553-563, 2006.

[4] K.-H. Cho, Y.-S. Kim, H.-S. Bae et al., "Inhibitory effect of Chunghyuldan in prostaglandin E2 and nitric oxide biosynthesis of lipopolysaccharide-induced RAW 264.7 cells," Biological and Pharmaceutical Bulletin, vol. 27, no. 11, pp. 1810-1813, 2004.

[5] W. S. Jung, J. Cho, K. In et al., "Chunghyul-dan acts as an anti-Inflammatory agent in endothelial cells by regulating gene expression," Animal Cells and Systems, vol. 14, no. 4, pp. 275-282, 2010.

[6] G. H. Kim, J. W. Kim, S. Y. Chung et al., "The protective effect of Chunghul-dan(Quingwuedan) against 6-hydroxydopamine induced neurotoxicity," Journal of Oriental Neuropsychiatry, vol. 20, no. 1, pp. 21-42, 2009.

[7] S. P. Yun, W. S. Jung, S. U. Park et al., "Anti-hypertensive effect of Chunghyul-dan (Qingxue-dan) on stroke patients with essential hypertension," American Journal of Chinese Medicine, vol. 33, no. 3, pp. 357-364, 2005.

[8] K. N. Nam, H.-J. Jung, M.-H. Kim et al., "Chunghyuldan attenuates brain microglial inflammatory response," Canadian Journal of Physiology and Pharmacology, vol. 87, no. 6, pp. 448-454, 2009.

[9] H. G. Kim, M. S. Ju, D.-H. Kim et al., "Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease," Basic and Clinical Pharmacology and Toxicology, vol. 107, no. 6, pp. 958-964, 2010.

[10] C.-N. Ko, I.-S. Park, S.-U. Park et al., "Neuroprotective effect of Chunghyuldan (Qing Xue Dan) on hypoxia-reoxygenation induced damage of neuroblastoma 2a cell lines," Chinese Journal of Integrative Medicine, vol. 19, no. 12, pp. 940-944, 2013.

[11] S.-U. Park, W.-S. Jung, S.-K. Moon et al., "Chunghyuldan activates NOS mRNA expression and suppresses VCAM-1 mRNA expression in human endothelial cells," Canadian Journal of Physiology and Pharmacology, vol. 83, no. 12, pp. 1101-1108, 2005.

[12] K. Cho, K. Noh, W. Jung et al., "A preliminary study on the inhibitory effect of Chunghyul-dan on stroke recurrence in patients with small vessel disease," Neurological Research, vol. 30, no. 6, pp. 655-658, 2008.

[13] J. M. Wardlaw, A. Farrall, P. A. Armitage et al., "Changes in background blood-brain barrier integrity between lacunar and cortical ischemic stroke subtypes," Stroke, vol. 39, no. 4, pp. 1327-1332, 2008.

[14] M. Silvestrini, F. Vernieri, P. Pasqualetti et al., "Impaired cerebral vasoreactivity and risk of stroke in patients with asymptomatic carotid artery stenosis," Journal of the American Medical Association, vol. 283, no. 16, pp. 2122-2127, 2000.

[15] Y. J. Lee, W. Jy, L. L. Horstman et al., "Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias," Thrombosis Research, vol. 72, no. 4, pp. 295-304, 1993.

[16] R. B. Panerai, S. L. Dawson, P. J. Eames, and J. F. Potter, "Cerebral blood flow velocity response to induced and spontaneous sudden changes in arterial blood pressure," American Journal of Physiology--Heart and Circulatory Physiology, vol. 280, no. 5, pp. H2162-H2174, 2001.

[17] P. A. Low, V. Novak, J. M. Spies, P. Novak, and G. W. Petty, "Cerebrovascular regulation in the postural orthostatic tachycardia syndrome (POTS)," The American Journal of the Medical Sciences, vol. 317, no. 2, pp. 124-133, 1999.

[18] R. F. Leoni, F. F. Paiva, E. C. Henning et al., "Magnetic resonance imaging quantification of regional cerebral blood flow and cerebrovascular reactivity to carbon dioxide in normotensive and hypertensive rats," NeuroImage, vol. 58, no. 1, pp. 75-81, 2011.

[19] G. M. Kozera, B. Wolnik, K. B. Kunicka et al., "Cerebrovascular reactivity, intima-media thickness, and nephropathy presence in patients with type 1 diabetes," Diabetes Care, vol. 32, no. 5, pp. 878-882, 2009.

[20] V. Vuletic, L. Cengic, S. Basic et al., "Impaired cerebral vasore-activity in type 2 diabetes mellitus," Collegium Antropologicum, vol. 35, no. 1, pp. 27-31, 2011.

[21] D. Georgiadis, M. Sievert, S. Cencetti et al., "Cerebrovascular reactivity is impaired in patients with cardiac failure," European Heart Journal, vol. 21, no. 5, pp. 407-413, 2000.

[22] H. Markus and M. Cullinane, "Severely impaired cerebrovascular reactivity predicts stroke and TIA risk in patients with carotid artery stenosis and occlusion," Brain, vol. 124, no. 3, pp. 457-467, 2001.

[23] R. L. Rogers, J. S. Meyer, K. F. Mortel, R. K. Mahurin, and J. Thornby, "Age-related reductions in cerebral vasomotor reactivity and the law of initial value: a 4-year prospective longitudinal study," Journal of Cerebral Blood Flow and Metabolism, vol. 5, no. 1, pp. 79-85, 1985.

[24] E. Vicenzini, M. C. Ricciardi, M. Altieri et al., "Cerebrovascular reactivity in degenerative and vascular dementia: a transcranial doppler study," European Neurology, vol. 58, no. 2, pp. 84-89, 2007.

[25] A. G.-C. de Castro, M. Bajbouj, P. Schlattmann, H. Lemke, I. Heuser, and P. Neu, "Cerebrovascular reactivity in depressed patients without vascular risk factors," Journal of Psychiatric Research, vol. 42, no. 1, pp. 78-82, 2008.

[26] S. Cantin, M. Villien, O. Moreaud et al., "Impaired cerebral vasoreactivity to C[O.sub.2] in Alzheimer's disease using BOLD fMRI," NeuroImage, vol. 58, no. 2, pp. 579-587, 2011.

[27] S. L. M. Bakker, F.-E. De Leeuw, J. C. De Groot, A. Hofman, P. J. Koudstaal, and M. M. B. Breteler, "Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly," Neurology, vol. 52, no. 3, pp. 578-583, 1999.

[28] C. Molina, J. A. Sabin, J. Montaner, A. Rovira, S. Abilleira, and A. Codina, "Impaired cerebrovascular reactivity as a risk marker for first-ever lacunar infarction: a case-control study," Stroke, vol. 30, no. 11, pp. 2296-2301, 1999.

[29] M. Liu and L. Zhou, "Cerebrovascular reserve may be a more accurate predictor of stroke than degree of ICA or MCA stenosis," Medical Science Monitor, vol. 20, pp. 2082-2087, 2014.

[30] P. Palazzo, P. Maggio, F. Passarelli et al., "Lack of correlation between cerebral vasomotor reactivity and flow-mediated dilation in subjects without vascular disease," Ultrasound in Medicine and Biology, vol. 39, no. 1, pp. 10-15, 2013.

[31] J. Pretnar-Oblak, M. Sabovic, and M. Zaletel, "Associations between systemic and cerebral endothelial impairment determined by cerebrovascular reactivity to L-arginine," Endothelium, vol. 14, no. 2, pp. 73-80, 2007.

[32] Y. Izumi, Y. Tsuda, S.-I. Ichihara, T. Takahashi, and H. Matsuo, "Effects of defibrination on hemorheology, cerebral blood flow velocity, and C[O.sub.2] reactivity during hypocapnia in normal subjects," Stroke, vol. 27, no. 8, pp. 1328-1332, 1996.

[33] D. W. Jeong, S. K. Moon, J. W. Hong et al., "Effects of Korean ginseng, Korean red ginseng and fermented Korean red ginseng on cerebral blood flow, cerebrovascular reactivity, systemic blood pressure and pulse rate in humans," Journal of Korean Oriental Medicine, vol. 27, pp. 38-50, 2006.

[34] W.-S. Jung, J.-Y. Park, H.-S. Byeon et al., "Effects of Hyul-BuChuke-ang on erythrocyte deformability and cerebrovascular C[O.sub.2] reactivity in normal subjects," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 725241, 7 pages, 2012.

[35] T. M. Markwalder, P. Grolimund, R. W. Seiler, F. Roth, and R. Aaslid, "Dependency of blood flow velocity in the middle cerebral artery on end-tidal carbon dioxide partial pressure--a transcranial ultrasound doppler study," Journal of Cerebral Blood Flow and Metabolism, vol. 4, no. 3, pp. 368-372, 1984.

[36] K.-H. Cho, W.-S. Jung, S.-U. Park et al., "Daio-Orengedokudo works as a cell-proliferating compound in endothelial cells," Canadian Journal of Physiology and Pharmacology, vol. 82, no. 6, pp. 380-386, 2004.

[37] W. H. Kaesemeyer, R. B. Caldwell, J. Huang, and R. William Caldwell, "Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions," Journal of the American College of Cardiology, vol. 33, no. 1, pp. 234-241, 1999.

[38] P. Sterzer, F. Meintzschel, A. Rosler, H. Lanfermann, H. Steinmetz, and M. Sitzer, "Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease," Stroke, vol. 32, no. 12, pp. 2817-2820, 2001.

[39] K. Sander, U. Hof, H. Poppert, B. Conrad, and D. Sander, "Improved cerebral vasoreactivity after statin administration in healthy adults," Journal of Neuroimaging, vol. 15, no. 3, pp. 266-270, 2005.

[40] W. Sorteberg, K.-F. Lindegaard, K. Rootwelt et al., "Blood velocity and regional blood flow in defined cerebral artery systems," Acta Neurochirurgica, vol. 97, no. 1-2, pp. 47-52, 1989.

[41] K. F. Lindegaard, T. Lundar, J. Wiberg, D. Sjoberg, R. Aaslid, and H. Nornes, "Variations in middle cerebral artery blood flow investigated with noninvasive transcranial blood velocity measurements," Stroke, vol. 18, no. 6, pp. 1025-1030, 1987.

[42] H. Girouard and C. Iadecola, "Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease," Journal of Applied Physiology, vol. 100, no. 1, pp. 328-335, 2006.

[43] T. C. De Toledo Ferraz Alves and G. F. Busatto, "Regional cerebral blood flow reductions, heart failure and Alzheimer's disease," Neurological Research, vol. 28, no. 6, pp. 579-587, 2006.

[44] D. H. Salat, R. L. Buckner, A. Z. Snyder et al., "Thinning of the cerebral cortex in aging," Cerebral Cortex, vol. 14, no. 7, pp. 721-730, 2004.

[45] J. J. Chen, H. D. Rosas, and D. H. Salat, "Age-associated reductions in cerebral blood flow are independent from regional atrophy," NeuroImage, vol. 55, no. 2, pp. 468-478, 2011.

[46] S. Joshi, W. L. Young, H. Duong et al., "Intracarotid nitroprusside does not augment cerebral blood flow in human subjects," Anesthesiology, vol. 96, no. 1, pp. 60-66, 2002.

[47] S. Lavi, R. Egbarya, R. Lavi, and G. Jacob, "Role of nitric oxide in the regulation of cerebral blood flow in humans: chemoregulation versus mechanoregulation," Circulation, vol. 107, no. 14, pp. 1901-1905, 2003.

[48] R. P. White, C. Deane, C. Hindley et al., "The effect of the nitric oxide donor glyceryl trinitrate on global and regional cerebral blood flow in man," Journal of the Neurological Sciences, vol. 178, no. 1, pp. 23-28, 2000.

[49] R. W. Seiler and A. C. Nirkko, "Effect of nimodipine on cerebrovascular response to C[O.sub.2] in asymptomatic individuals and patients with subarachnoid hemorrhage: a transcranial Doppler ultrasound study," Neurosurgery, vol. 27, no. 2, pp. 247-251, 1990.

[50] D. Canova, S. Roatta, G. Micieli, and D. Bosone, "Cerebral oxygenation and haemodynamic effects induced by nimodipine in healthy subjects," Functional Neurology, vol. 27, no. 3, pp. 169-176, 2012.

[51] S. Moncada, R. M. J. Palmer, and E. A. Higgs, "Nitric oxide: physiology, pathophysiology, and pharmacology," Pharmacological Reviews, vol. 43, no. 2, pp. 109-142, 1991.

[52] R. P. Patel, A.-L. Levonen, J. H. Crawford, and V. M. Darley-Usmar, "Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis," Cardiovascular Research, vol. 47, no. 3, pp. 465-474, 2000.

[53] F. M. Ho, S. H. Liu, C. S. Liau, P. J. Huang, S. G. Shiah, and S. Y. Lin-Shiau, "Nitric oxide prevents apoptosis of human endothelial cells from high glucose exposure during early stage," Journal of Cellular Biochemistry, vol. 75, no. 2, pp. 258-263, 1999.

[54] R. P. White, C. Deane, P. Vallance, and H. S. Markus, "Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia," Stroke, vol. 29, no. 2, pp. 467-472, 1998.

[55] M. Okamoto, H. Etani, Y. Yagita, N. Kinoshita, and T.-A. Nukada, "Diminished reserve for cerebral vasomotor response to L-arginine in the elderly: evaluation by transcranial Doppler sonography," Gerontology, vol. 47, no. 3, pp. 131-135, 2001.

[56] C. Zimmermann and R. L. Haberl, "L-arginine improves diminished cerebral C[O.sub.2] reactivity in patients," Stroke, vol. 34, no. 3, pp. 643-647, 2003.

[57] A. M. Kamper, A. Spilt, A. J. M. De Craen, M. A. Van Buchem, R. G. J. Westendorp, and G. J. Blauw, "Basal cerebral blood flow is dependent on the nitric oxide pathway in elderly but not in young healthy men," Experimental Gerontology, vol. 39, no. 8, pp. 1245-1248, 2004.

[58] K. Ide, M. Worthley, T. Anderson, and M. J. Poulin, "Effects of the nitric oxide synthase inhibitor L-NMMA on cerebrovascular and cardiovascular responses to hypoxia and hypercapnia in humans," Journal of Physiology, vol. 584, no. 1, pp. 321-332, 2007.

[59] J. Strohm, J. Duffin, and J. A. Fisher, "Circadian cerebrovascular reactivity to C[O.sub.2]," Respiratory Physiology and Neurobiology, vol. 197, no. 1, pp. 15-18, 2014.

[60] D. A. Conroy, A. J. Spielman, and R. Q. Scott, "Daily rhythm of cerebral blood flow velocity," Journal of Circadian Rhythms, vol. 3, article 3, 2005.

Chul Jin, Sang-Kwan Moon, Seung-Yeon Cho, Seong-Uk Park, Woo-Sang Jung, Jung-Mi Park, Chang-Nam Ko, Ki-Ho Cho, and Seungwon Kwon

Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea

Correspondence should be addressed to Seungwon Kwon; kkokkottung@hanmail.net

Received 23 January 2017; Revised 6 March 2017; Accepted 9 March 2017; Published 20 April 2017

Academic Editor: Yoshiji Ohta

Caption: Figure 1: Study design timeline. Measurements were repeated four times, at least 1 week apart, according to the multiple-crossover design. CHD, chunghyul-dan; hr, hour; HR, heart rate; BP, blood pressure; TCD, transcranial Doppler sonography; hypervent., hyperventilation.

Caption: Figure 2: Percent changes in C[O.sub.2] reactivity (%) before and after CHD administration. The lines represent the means [+ or -] SEM. CHD, chunghyuldan; hr, hour. (#) p < 0.05 versus control at the same time points by Bonferroni multiple comparisons after one-way repeated measures analysis of variation (RM ANOVA). * p < 0.05 versus CHD 300 mg at the same time points by Bonferroni multiple comparisons after one-way RM ANOVA.

Caption: Figure 3: Percent changes in CV40 (%) before and after CHD administration. Values are means [+ or -] SEM. CHD, chunghyul-dan; hr, hour. (#) p < 0.05 versus control at the same time points by Bonferroni multiple comparisons after one-way repeated measures analysis of variation (RM ANOVA). * p < 0.05 versus CHD 300 mg at the same time points by Bonferroni multiple comparisons after one-way RM ANOVA.

Caption: Figure 4: Pearson's correlation analysis of the changes in C[O.sub.2] reactivity and CV40 before and after CHD administration. A significant correlation is shown between CHD administration-mediated changes in C[O.sub.2] reactivity and the CV40 of the MCA (p < 0.001, r = 0.621).
Table 1: Constituents of chunghyul-dan (CHD).

                                              Part    Weight (g/
Components                                    used     capsule)

Scutellaria baicalensis Georgi (Labiatae)     Root       0.28
Coptis japonica Makino (Ranunculaceae)        Root       0.28
Phellodendron amurense Ruprecht (Rutaceae)   Cortex      0.28
Gardenia jasminoides Ellis (Rubiaceae)       Fruit       0.28
Rheum palmatum L. (Polygonaceae)              Root       0.07

Total                                                    1.2

Table 2: Changes in hyperventilation-induced C[O.sub.2] reactivity
(%/min) before and after CHD administration.

                                       After administration
                   (T0) Before
(n = 12)          administration            T1 (1hr)

Control         2.16 [+ or -] 0.42       2.08 [+ or -] 0.39
CHD   300 mg    2.07 [+ or -] 0.34       2.06 [+ or -] 0.51
CHD   600 mg    2.06 [+ or -] 0.31   2.37 (#) [+ or -] 0.39
CHD   1200 mg   2.00 [+ or -] 0.25       2.24 [+ or -] 0.28

                              After administration

(n = 12)               T2 (2hr)                 T3 (3hr)

Control             1.93 [+ or -] 0.33       1.99 [+ or -] 0.36
CHD   300 mg        2.02 [+ or -] 0.36       1.94 [+ or -] 0.43
CHD   600 mg    2.56 (#) [+ or -] 0.42   2.64 (#) [+ or -] 0.44
CHD   1200 mg   2.35 (#) [+ or -] 0.38   2.53 (#) [+ or -] 0.30

                               p ([double
(n = 12)        p ([dagger])    dagger])     p *

Control            <0.001          --       0.090
CHD   300 mg                     1.000      0.501
CHD   600 mg                     0.024      <0.001
CHD   1200 mg                    0.034      <0.001

All data are means [+ or -] SD. CHD, chunghyul-dan; hr, hour.

([dagger]) p: time x treatment interaction effect by two-way repeated
measures analysis of variation (RM ANOVA).

([double dagger]) p: post hoc test by Bonferroni multiple comparisons
versus control after two-way RM ANOVA.

* p: within-measure (time) effect by one-way RM ANOVA.

(#) p < 0.05 versus before administration (baseline) by Bonferroni
multiple comparisons after one-way RM ANOVA.

Table 3: Changes in corrected blood flow velocity at [P.sub.ETCO2] =
40 mmHg (CV40, cm/sec) before and after CHD administration.

                                     After administration
                   (T0) Before
(n = 12)          administration          T1 (1hr)

Control         54.7 [+ or -] 8.77   54.3 [+ or -] 8.87
CHD   300 mg    54.4 [+ or -] 7.28   53.2 [+ or -] 8.37
CHD   600 mg    51.4 [+ or -] 9.49   52.4 [+ or -] 10.69
CHD   1200 mg   52.2 [+ or -] 7.34   53.3 [+ or -] 7.53

                           After administration

(n = 12)             T2 (2hr)              T3 (3hr)

Control         54.1 [+ or -] 9.30    52.2 [+ or -] 9.69
CHD   300 mg    52.8 [+ or -] 7.62    52.1 [+ or -] 9.13
CHD   600 mg    52.7 [+ or -] 11.39   55.2 [+ or -] 12.92
CHD   1200 mg   53.5 [+ or -] 8.88    54.8 [+ or -] 7.70

(n = 12)        p ([dagger])    p *

Control            0.002       0.071
CHD   300 mg                   0.061
CHD   600 mg                   0.024
CHD   1200 mg                  0.255

Mean [+ or -] SD values are shown. CHD, chunghyul-dan; hr, hour.

([dagger]) p: time x treatment interaction by two-way repeated
measures analysis of variation (RM ANOVA).

No significant difference between each group (Bonferroni multiple
comparisons).

* p: time effect of individual treatment by one-way RM ANOVA.

No significant difference between individual time points (Bonferroni
multiple comparisons).

Table 4: Changes in mean blood pressure and heart rate before
and after CHD administration.

                                     After administration
                   (T0) Before
(n = 12)          administration          T1 (1hr)

                      Mean blood pressure (mmHg)

   Control      84.5 [+ or -] 4.57   84.8 [+ or -] 5.27
CHD   300 mg    84.3 [+ or -] 2.87   83.6 [+ or -] 3.21
CHD   600 mg    82.3 [+ or -] 4.16   83.6 [+ or -] 4.02
CHD   1200 mg   83.4 [+ or -] 4.79   84.4 [+ or -] 5.25

                     Heart rate (beats per minute)

   Control      66.7 [+ or -] 9.47   65.6 [+ or -] 8.63
CHD   300 mg    66.5 [+ or -] 6.24   65.8 [+ or -] 6.41
CHD   600 mg    65.2 [+ or -] 9.00   65.1 [+ or -] 9.79
CHD   1200 mg   63.7 [+ or -] 9.26   64.3 [+ or -] 7.71

                         After administration

(n = 12)             T2 (2hr)             T3 (3hr)

                      Mean blood pressure (mmHg)

   Control      85.4 [+ or -] 4.81   85.2 [+ or -] 4.32
CHD   300 mg    83.3 [+ or -] 4.47   83.4 [+ or -] 4.67
CHD   600 mg    82.9 [+ or -] 5.26   83.4 [+ or -] 5.07
CHD   1200 mg   84.9 [+ or -] 4.02   84.7 [+ or -] 4.09

                     Heart rate (beats per minute)

   Control      64.8 [+ or -] 8.36   65.0 [+ or -] 9.47
CHD   300 mg    64.6 [+ or -] 7.06   65.2 [+ or -] 6.39
CHD   600 mg    63.7 [+ or -] 8.58   64.3 [+ or -] 7.68
CHD   1200 mg   63.9 [+ or -] 9.73   62.8 [+ or -] 8.64

(n = 12)        p ([dagger])    p *

                Mean blood pressure (mmHg)

   Control         0.742       0.736
CHD   300 mg                   0.695
CHD   600 mg                   0.611
CHD   1200 mg                  0.518

                Heart rate (beats per minute)

   Control         0.791       0.154
CHD   300 mg                   0.085
CHD   600 mg                   0.374
CHD   1200 mg                  0.356

All data are means [+ or -] SD. CHD, chunghyul-dan; hr, hour.

([dagger] p: time x treatment interaction by two- way repeated measures
analysis of variation (RM ANOVA).

* p: time effect of individual groups by one-way RM ANOVA.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Jin, Chul; Moon, Sang-Kwan; Cho, Seung-Yeon; Park, Seong-Uk; Jung, Woo-Sang; Park, Jung-Mi; Ko, Chan
Publication:Evidence - Based Complementary and Alternative Medicine
Article Type:Report
Date:Jan 1, 2017
Words:6818
Previous Article:Retracted: The Effect of Elephantopus scaber L. on Liver Regeneration after Partial Hepatectomy.
Next Article:Effect of Taichi Softball on Function-Related Outcomes in Older Adults: A Randomized Control Trial.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |